Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage

NCT01893190 is registered in ClinicalTrials.gov with Edge Therapeutics Inc as lead sponsor.

NCT NCT01893190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01893190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage
Lead sponsor
Edge Therapeutics Inc
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2013
Completion date
January 31, 2016
Enrollment
73 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

ruptured berry aneurysm, ruptured cerebral aneurysm